Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.
G-CON Manufacturing and Pall Corporation are collaborating to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry. G-CON PODs will be customized with advanced Pall Biotech bioprocess equipment, including automation and utility supplies; these will be predesigned into the G-CON cleanroom units for scalable deployment.
“Together, Pall’s cutting-edge technology and G-CON’s flexible cleanroom platform take the concept of modularity one step further, delivering a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitize and even repurpose,” said Mario Philips, Vice President & General Manager at Pall Biotech. “This strategic collaboration is particularly important to Pall, as we continuously improve bioprocesses for the industry by offering innovative solutions like G-CON PODs customized with Pall technologies. This solution addresses customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing.”
PODs from G-CON are mobile, and include integrated process piping and heating and air conditioning (HVAC) systems. Deploying the customized PODs is simple by design, allowing a customer to focus on the target molecule, while relying on the G-CON and Pall teams to optimize the facility design and process. Once designed, the PODs ease verification, qualification and validation challenges by providing comprehensive site acceptance testing and even IQ/OQ support. The PODs’ flexibility allows them to support multiple products, and they can be easily repurposed. In addition, the cost of 'building' a facility is drastically reduced, as is build time, which increases the return on investment.
“G-CON’s prefabricated cleanroom units feature a complete, yet compressed footprint for Pall’s continuous bioprocessing and viral vector production designs. The implementation of the Pall processes into our POD infrastructure creates an ideal turnkey solution for our customers. These solutions will be readily deployable and scalable, as they reduce the typical design, verification and qualification efforts by standardizing processes and cleanroom environments,” said Maik Jornitz, President and CEO of G-CON Manufacturing. “We are looking forward to combining our PODs with Pall’s process knowledge and designs to serve our joint customer base. The industry requires optimized, fast, scalable solutions, and these requirements will be met through this collaboration.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance